Provectus Biopharmaceuticals, Inc. has retained INC Research to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit, conducted in two phases, is expected to be complete early November 2014.   In the first phase, INC will undertake a regulatory document inventory and evaluation of the contents of Provectus’ information management system (the Smart Room). The results of which will generate a document request list, and the second phase will involve further ...